Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cipla Sees Growth In Product-Based Alliances; In Deal With Teva For Inhalers In Russia

This article was originally published in PharmAsia News

Executive Summary

India’s second largest drug maker draws newer strategies to keep pace with emerging markets’ growth momentum, Cipla Chairman Yusuf Hamied tells PharmAsia News in an exclusive interview.

You may also be interested in...

Not Selling Yet, Cipla Opposes Capping MNC-led Buyouts Of Indian Firms

MUMBAI - Cipla Ltd. Chairman Yusuf K. Hamied has tried to temper nagging speculation over a possible sell-off to a global company like Merck & Co. or Takeda Pharmaceutical Co. Ltd. He emphatically denied holding any negotiations and claimed he has never been approached for a potential transaction

Indian Investors Turn Cautious On Compliance Concerns

A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.

Lee Takes India Compulsory License Fight To Saxagliptin

In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts